BOSTON, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company advancing precision medicine through its first-in-class comprehensive epigenomic liquid biopsy platform, today announced the ...

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S ®), an investigational folate receptor alpha ...

The data represent the first clinical trial results of a 212Pb-based PSMA therapy. The findings support the further development of 212Pb-ADVC001 and may offer a new reference point in the treatment ...

Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT / 1:30 p.m. ET / 7:30 p.m. CEST ...

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with ...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups ; Median PFS was 15.5 months in the 120 mg palazestrant cohort ...

The six-month rPFS rate and median rPFS for patients from both arms combined was 67% and 9.1 months, respectively. For patients treated with 120 mg gedatolisib, the six-month rPFS rate was 74% and ...

The ongoing CRB-701 Phase 1/2 clinical trial ( NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high ...

Earlier this month, Company CEO Ryoji Baba was officially invited by the Embassy of Japan in Vietnam and appointed as a Board Member of United Nations-affiliated non-governmental organization (“NGO”) ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy; JADE101 is an investigational, p ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients; Vision improvements ...